BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 20603498)

  • 1. Influence of seasonal variations in ambient temperatures on performance of immunochemical faecal occult blood test for colorectal cancer screening: observational study from the Florence district.
    Grazzini G; Ventura L; Zappa M; Ciatto S; Confortini M; Rapi S; Rubeca T; Visioli CB; Halloran SP
    Gut; 2010 Nov; 59(11):1511-5. PubMed ID: 20603498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of sample return time and ambient temperature on the performance of an immunochemical faecal occult blood test with a new buffer for colorectal cancer screening.
    Dancourt V; Hamza S; Manfredi S; Drouillard A; Bidan JM; Faivre J; Lepage C
    Eur J Cancer Prev; 2016 Mar; 25(2):109-14. PubMed ID: 25830897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of colorectal adenomas by a quantitative immunochemical faecal occult blood screening test depends on adenoma characteristics, development threshold used and number of tests performed.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Leshno M; Niv Y
    Aliment Pharmacol Ther; 2009 Apr; 29(8):906-17. PubMed ID: 19183147
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population.
    van Rossum LG; van Rijn AF; Laheij RJ; van Oijen MG; Fockens P; van Krieken HH; Verbeek AL; Jansen JB; Dekker E
    Gastroenterology; 2008 Jul; 135(1):82-90. PubMed ID: 18482589
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of season and ambient temperature on outcome of guaiac-based faecal occult blood tests performed for colorectal cancer screening.
    Hunter JP; Saratzis A; Froggatt P; Harmston C
    Colorectal Dis; 2012 Sep; 14(9):1084-9. PubMed ID: 22122559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analytical comparison of three quantitative immunochemical fecal occult blood tests for colorectal cancer screening.
    Guittet L; Guillaume E; Levillain R; Beley P; Tichet J; Lantieri O; Launoy G
    Cancer Epidemiol Biomarkers Prev; 2011 Jul; 20(7):1492-501. PubMed ID: 21576271
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Performance characteristics and evaluation of an automated-developed and quantitative, immunochemical, fecal occult blood screening test.
    Vilkin A; Rozen P; Levi Z; Waked A; Maoz E; Birkenfeld S; Niv Y
    Am J Gastroenterol; 2005 Nov; 100(11):2519-25. PubMed ID: 16279909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost evaluation in a colorectal cancer screening programme by faecal occult blood test in the District of Florence.
    Grazzini G; Ciatto S; Cislaghi C; Castiglione G; Falcone M; Mantellini P; Zappa M;
    J Med Screen; 2008; 15(4):175-81. PubMed ID: 19106257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
    Quintero E
    Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics.
    Allison JE; Sakoda LC; Levin TR; Tucker JP; Tekawa IS; Cuff T; Pauly MP; Shlager L; Palitz AM; Zhao WK; Schwartz JS; Ransohoff DF; Selby JV
    J Natl Cancer Inst; 2007 Oct; 99(19):1462-70. PubMed ID: 17895475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of FOBT-assessed faecal Hb content with colonic lesions detected in the Florence screening programme.
    Ciatto S; Martinelli F; Castiglione G; Mantellini P; Rubeca T; Grazzini G; Bonanomi AG; Confortini M; Zappa M
    Br J Cancer; 2007 Jan; 96(2):218-21. PubMed ID: 17211476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can patients at high risk for significant colorectal neoplasms and having normal quantitative faecal occult blood test postpone elective colonoscopy?
    Hazazi R; Rozen P; Leshno M; Levi Z; Samuel Z; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2010 Feb; 31(4):523-33. PubMed ID: 19925498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity of latex agglutination faecal occult blood test in the Florence District population-based colorectal cancer screening programme.
    Castiglione G; Visioli CB; Ciatto S; Grazzini G; Bonanomi AG; Rubeca T; Mantellini P; Zappa M
    Br J Cancer; 2007 Jun; 96(11):1750-4. PubMed ID: 17453007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized trial of different screening strategies for colorectal cancer: patient response and detection rates.
    Segnan N; Senore C; Andreoni B; Arrigoni A; Bisanti L; Cardelli A; Castiglione G; Crosta C; DiPlacido R; Ferrari A; Ferraris R; Ferrero F; Fracchia M; Gasperoni S; Malfitana G; Recchia S; Risio M; Rizzetto M; Saracco G; Spandre M; Turco D; Turco P; Zappa M;
    J Natl Cancer Inst; 2005 Mar; 97(5):347-57. PubMed ID: 15741571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunochemical testing of individuals positive for guaiac faecal occult blood test in a screening programme for colorectal cancer: an observational study.
    Fraser CG; Matthew CM; Mowat NA; Wilson JA; Carey FA; Steele RJ
    Lancet Oncol; 2006 Feb; 7(2):127-31. PubMed ID: 16455476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms.
    Rozen P; Levi Z; Hazazi R; Waked A; Vilkin A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2009 Feb; 29(4):450-7. PubMed ID: 19035980
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Testing for faecal calprotectin (PhiCal) in the Norwegian Colorectal Cancer Prevention trial on flexible sigmoidoscopy screening: comparison with an immunochemical test for occult blood (FlexSure OBT).
    Hoff G; Grotmol T; Thiis-Evensen E; Bretthauer M; Gondal G; Vatn MH
    Gut; 2004 Sep; 53(9):1329-33. PubMed ID: 15306594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer.
    Faivre J; Dancourt V; Denis B; Dorval E; Piette C; Perrin P; Bidan JM; Jard C; Jung S; Levillain R; Viguier J; Bretagne JF
    Eur J Cancer; 2012 Nov; 48(16):2969-76. PubMed ID: 22572481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
    Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
    Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.